Key Drivers
- Strong liquidity
- Low net returns
- High intangibles
AIAI Summary
Envista's investment case has shifted from a cyclical recovery into an execution- and margin-driven story—valuation depends on sustained Spark/implant/diagnostics-led gross-margin expansion and consistent conversion of revenue into free cash flow without further inventory/capex drag, while China VBP and tariff-related headwinds represent the single biggest risk that would quickly reverse upside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong liquidity
- •Low net returns
- •High intangibles
Strong liquidity and FCF provide a buffer, but NVST's very low net returns, large intangibles and noncurrent debt, and premium multiples imply the market is pricing significant profit improvement that isn't yet evident.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Lower lows
- •Elevated volatility
Stock dropped from about $29.12 to $24.89 over the last month, trading below its last-month SMA and showing a bearish trend with immediate support near the mid-$24s and resistance in the $27–$29 area.
Elevated intraday volatility and a sharp decline from $29.12 to $24.89 over the last month
Sentiment & News
Key News Insights:
- •Zacks upgrades
- •Technical momentum
- •Institutional trim
Analysts have increased bullish coverage on Envista with Zacks upgrades and technical/earnings momentum in Feb–Mar 2026, offset by a modest institutional trim and peer-comparison scrutiny.
The mix of analyst upgrades and upward earnings revisions suggests moderate upside potential, though peer scrutiny and a small stake reduction cap immediate re-rating
Similar Companies in Healthcare
Other companies in the same sector with AI ratings